AbbVie Inc.
Close on Nov 2, 2026Market cap $510.41BP/E 81.6Yield 2.30%
AbbVie AndroGel [legacy through FY20Q1] by Year
AndroGel (testosterone gel) [legacy through FY20Q1] — U.S. net revenues ($M) ($M)
AbbVie AndroGel [legacy through FY20Q1]: $172M in FY2019, down 63.3% from a year earlier. No newer figure appears in the documents we track.
Where the FY2019 figure comes from
Source: Form 10-K (filed 2020-02-21) ↗
Reported in Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Key Product Revenues.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | AndroGel (testosterone gel) [legacy through FY20Q1] — U.S. net revenues ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2019 | Dec 31, 2019 | 172 | -63.3% | Form 10-K (filed 2020-02-21) ↗ |
| FY2018 | Dec 31, 2018 | 469 | -18.7% | Form 10-K (filed 2020-02-21) ↗ |
| FY2017 | Dec 31, 2017 | 577 | -14.5% | Form 10-K (filed 2020-02-21) ↗ |
| FY2016 | Dec 31, 2016 | 675 | – | Form 10-K (filed 2019-02-27) ↗ |
Cite this data
StockData. (2026). AbbVie AndroGel [legacy through FY20Q1] ($M), annual FY2016–FY2019 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/androgel-us
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.